US 11,723,901 B2
Uses of piperidinyl-indole derivatives
Jörg Eder, Rheinfelden (DE); Richard Alexander Harrison, Shropshire (GB); Boerje Haraldsson, Basel (CH); and Anna Svenja Schubart, Basel (CH)
Assigned to Novartis AG, Basel (CH)
Appl. No. 16/642,905
Filed by NOVARTIS AG, Basel (CH)
PCT Filed Aug. 30, 2018, PCT No. PCT/IB2018/056618
§ 371(c)(1), (2) Date Feb. 28, 2020,
PCT Pub. No. WO2019/043609, PCT Pub. Date Mar. 7, 2019.
Claims priority of application No. 17188870 (EP), filed on Aug. 31, 2017.
Prior Publication US 2020/0338059 A1, Oct. 29, 2020
Int. Cl. A61K 31/445 (2006.01); A61K 31/454 (2006.01); A61P 13/12 (2006.01)
CPC A61K 31/454 (2013.01) [A61P 13/12 (2018.01)] 14 Claims
 
1. A method of treating IgAN (immuneglobuline A nephropathy), in a patient suffering therefrom, comprising the step of administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to said patient, wherein

OG Complex Work Unit Chemistry
R is hydrogen, C1-C4alkyl, or C1-C6alkoxy;
R1 is C1-C6alkoxy;
R2 is C1-C6alkyl;
R3 is C1-C6alkoxy; C1-C6alkyl; or hydroxyl;
R4 is phenyl, optionally substituted by —C(O)R8, and
R8 is hydroxy, C1-C4alkoxy, or amino.